United States: The first- ever blessing of MDMA, the mind- altering club medicine, as a treatment for PTSD is being considered by civil health experts. This is a result of psychedelic activists’ decades-long battle to have the medicine’s supposed benefits accepted by drug.
Historic Consideration
Tuesday, the Food and Drug Administration brought together a group of outside specialists to examine the most recent data on the medication, which seems to indicate that when taken in conjunction with talk therapy, it can help alleviate post-traumatic stress disorder.
FDA Evaluation
However, FDA officials are skeptical about the validity of that information as well as the safety dangers associated with MDMA, which include the possibility of cardiac issues, injuries, and drug misuse.
The FDA panel is not obligated to abide by the group’s recommendations, but if they approve the medicine for PTSD, it may pave the way for federal approval later this summer. The panel will vote on the recommendation later on Tuesday.
Potential Approval Impact
If authorized, MDMA—also referred to as ecstasy or molly—would become the first illicit psychedelic to enter the mainstream of medical practice. The medication is the first of several psychedelics, including as LSD and psilocybin, that the FDA is anticipated to review in the coming years due to increasing interest in their potential to treat the conditions like depression addiction and anxiety.
The FDA has only approved antidepressants to treat PTSD at this time. PTSD is closely associated with sadness, anxiety, and suicidal thoughts and actions. Veterans and women are more likely to experience PTSD.
But the difficulties in researching and evaluating psychedelic drugs are brought to light by the FDA’s assessment of MDMA.
Challenges and Concerns
At the start of the conference on Tuesday, FDA reviewer Dr. Tiffany R. Farchione stated, “This application is both consequential and complex.”
Due to the strong psychological effects of MDMA, nearly every patient in two important trials of the drug could determine if they had taken a real pill or a fake one. In high-quality medication research, impartiality is typically essential so that patients cannot identify if they have received the drug under test. This is the reverse of what happens in this situation.
Farchione stated, “This makes it difficult to determine how much of the treatment effect is a true benefit and how much is due to expectation bias.”
In addition to that question, the FDA will pose a number of others to its outside panel, such as the question of how long MDMA’s potential benefits might last. Approximately 25% of patients left a follow-up study intended to monitor long-term results.
The drug’s safety hazards are another area of concern for FDA regulators. One such risk is whether patients could hurt themselves if the drug’s effects, which can linger for up to eight hours, continue to impair them. Elevated blood pressure is also linked to MDMA use.
Safety Measures and Support
The FDA has suggested stringent restrictions on the usage and locations of MDMA in the event that it is permitted due to these concerns. The medication could only be prescribed and administered by medical professionals who have received specialized training. It would be necessary to register and monitor patients throughout time. Additionally, medical personnel would need to be on hand to take the patients’ vital signs while they were taking the medication.
Lykos Therapeutics representatives stated on Tuesday that they supported these safety measures and believed they would speed up the drug’s licensing.
Dr. Kelley O’Donnell, a psychiatrist from New York University who cooperated with the MDMA trials, stated, “It’s evident that MDMA-assisted therapy would be a welcome addition to the currently available options.” “I have personally witnessed how this treatment can save some people’s lives.”
The Multidisciplinary Association for Psychedelic Studies, or MAPS, is the nation’s premier psychedelic advocacy group.
MAPS funded the studies, and Lykos is basically a corporate spinoff of MAPS. In order to promote the advantages of MDMA and other mind-altering substances, the group was established in 1986.
Support and Advocacy
Patients in the two key studies were given MDMA as part of a comprehensive four-month talk therapy program that included over a dozen sessions, just three of which included the drug’s administration. Patients who got MDMA had considerably reduced scores for PTSD after treatment.
Serotonin and dopamine are two feel-good brain chemicals that MDMA works on, and these interactions may enhance talk therapy. Experts surmise that the medication facilitates patients’ ability to face past traumas by lowering anxiety and improving their rapport and trust with therapists.
The Science and Educational Media Group of the Howard Hughes Medical Institute provides support to the Associated Press Health and Science Department. All content is the exclusive responsibility of the AP.